MedTrace Logo

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

NCT06226350 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-01-26

No results posted yet for this study

Summary

This study was an open, single-arm, enriched, multicenter Phase II study.

Conditions

Interventions

DRUG

Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection

F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.

Sponsors & Collaborators

  • Shandong New Time Pharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • QI ZHOU, MD · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2023-12-05
Completion
2024-01-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06226350 on ClinicalTrials.gov